Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX)

CUSIP: 22053A107

Q2 2019 13F Holders as of 30 Jun 2019

Type / Class
Equity / Common Stock, par value $0.0001 par value
Shares outstanding
55,541,178
Total 13F shares
2,421,805
Share change
+2,421,791
Total reported value
$102,945,360
Price per share
$42.51
Number of holders
37
Value change
+$102,944,765
Number of buys
36

Quarterly Holders Quick Answers

What is CUSIP 22053A107?
CUSIP 22053A107 identifies QNCX - Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX) as of Q2 2019

As of 30 Jun 2019, Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX) was held by 37 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,421,805 shares. The largest 10 holders included SC US (TTGP), LTD., Alphabet Inc., VANGUARD GROUP INC, BlackRock Inc., MANUFACTURERS LIFE INSURANCE COMPANY, THE, FMR LLC, DAFNA Capital Management LLC, GEODE CAPITAL MANAGEMENT, LLC, OxFORD Asset Management LLP, and GOLDMAN SACHS GROUP INC. This page lists 37 institutional shareholders reporting positions in this security for the Q2 2019 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.